Celltrion’s Herzuma (trastuzumab) is the first biosimilar of Roche’s blockbuster HER2-targeted therapy, Herceptin, to launch in Europe. This series tracks uptake of Herzuma and medical oncologists’ awareness of the agent in order to gauge its impact in the commercially lucrative breast cancer market and the gastroesophageal cancer market. The series investigates perceptions of Herzuma, drivers of and barriers to its use, and future-use expectations. Promotional efforts are explored, as well as prescriber and nonprescriber profiles, and benchmarking against other biosimilars, to better understand the dynamics of the German biosimilars market.
Emerging Biosimilars (Germany) is a three-wave series based on primary research data collected at 1 month, 6 months, and 12 months post-commercial launch with German physicians. The research captures physicians’ awareness, perceptions, and usage of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
Wave 1: September 2018
Wave 2: TBC 2019
Wave 3: TBC 2019
Survey of 60 medical oncologists
Key metrics included